{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:30:51Z","timestamp":1787761851636,"version":"build-2784847793"},"reference-count":51,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cancer patients have an increased risk of thromboembolic events. Consequently, anticoagulants such as rivaroxaban are often prescribed. With the increasing use of targeted therapies, there is a growing concern about potential drug\u2013drug interactions, as these therapies can affect metabolic enzymes and transporters (i.e., cytochrome P450 3A and P\u2010glycoprotein). When used in combination with rivaroxaban, these interactions may elevate a patient's risk of thromboembolic events or bleeding. Our primary objective was to investigate the effect of sotorasib on the pharmacokinetics of rivaroxaban and determine the safety of this combination in healthy volunteers. In an open label, single\u2010sequence, pharmacokinetic drug\u2013drug interaction study in healthy subjects, the influence of a once\u2010daily 960\u2009mg dose sotorasib for a period of 14\u2009days was evaluated on the pharmacokinetics of a single 20\u2009mg dose rivaroxaban. This clinical study followed the FDA guidance on drug interaction studies. A clinically relevant pharmacokinetic interaction was considered absent if the 90% confidence intervals (CIs) of the geometric mean ratios for\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    and AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    were within the no\u2010effect boundaries of 0.70\u20131.43. A total of 20 healthy subjects completed the study. The geometric mean ratios 1.00 (90% CI 0.90\u20131.12) for\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    and 0.79 (90% CI 0.73\u20130.86) for AUC\n                    <jats:sub>0\u2013\u221e<\/jats:sub>\n                    fell inside the predefined criteria, indicating no clinically relevant pharmacokinetic interaction. In addition, rivaroxaban and sotorasib were well tolerated by the healthy subjects. These results suggest that rivaroxaban can be safely co\u2010administered without the need for switching to another treatment or dose adjustments in patients treated with sotorasib.\n                  <\/jats:p>","DOI":"10.1002\/ijc.70326","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:15:28Z","timestamp":1768824928000},"page":"2920-2927","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["No relevant pharmacokinetic interaction between the\n                    <scp>KRAS G12C<\/scp>\n                    inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects"],"prefix":"10.1002","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5616-2064","authenticated-orcid":false,"given":"Esther M.","family":"Hollander","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology Research Institute for Medical Innovation, Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra I. G.","family":"Buma","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Research Institute for Medical Innovation, Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenneke","family":"Leentjens","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Research Institute for Medical Innovation, Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paddy K. C.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy VieCuri Medical Center  Venlo the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology Research Institute for Medical Innovation, Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berber","family":"Piet","sequence":"additional","affiliation":[{"name":"Department of Pulmonology Research Institute for Medical Innovation, Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology and Toxicology Research Institute for Medical Innovation, Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0119-2018"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-460121"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005590"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.10.021"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp030086"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(16)30092-5"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98062-0"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.02.022"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915103"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14662"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4059"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2350"},{"key":"e_1_2_12_16_1","unstructured":"European Medicines Agency (EMA).Xarelto: EPAR\u2010Product Information; 2023.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0004-2022"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02073-z"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02078-8"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02180-x"},{"key":"e_1_2_12_21_1","unstructured":"U.S. Food and Drug Administration (FDA).LUMAKRAS\u2014Highlights of Prescribing Information; 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214665s004lbl.pdf"},{"key":"e_1_2_12_22_1","unstructured":"European Medicines Agency (EMA).LUMYKRAS: EPAR\u2014Product Information; 2024.https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lumykras"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02717-6"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308795"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208470"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917239"},{"key":"e_1_2_12_27_1","unstructured":"DDI Manager\u2014Lung Cancer.https:\/\/ddimanager.co\/search\/lung-cancer"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02744-1"},{"key":"e_1_2_12_29_1","unstructured":"U.S. Food and Drug Administration (FDA).Clinical Drug Interaction Studies\u2014Study Design Data Analysis and Clinical Implications Guidance for Industry; 2017.https:\/\/www.regulations.gov\/document\/FDA-2017-D-5961-0002"},{"key":"e_1_2_12_30_1","unstructured":"U.S. Food and Drug Administration (FDA).M12 Drug Interaction Studies\u2014Guidance For Industry; 2024.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/m12\u2010drug\u2010interaction\u2010studies"},{"key":"e_1_2_12_31_1","unstructured":"National Cancer Institute (NCI).Common Terminology Criteria for Adverse Events (CTCAE) v6.0.https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_60"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0b013e31822f6c2b"},{"key":"e_1_2_12_33_1","unstructured":"European Medicines Agency (EMA).ICH Guideline M10 on Bioanalytical Method Validation and Study Sample Analysis; 2022.https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/ich\u2010guideline\u2010m10\u2010bioanalytical\u2010method\u2010validation\u2010step\u20105_en.pdf"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.5986"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847030-00006"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.2165\/11595320-000000000-00000"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.10.009"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-021-00319-1"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.042705"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13934"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802361499"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296058"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP201812"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14553"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0100-7"},{"key":"e_1_2_12_47_1","unstructured":"U.S. Food and Drug Administration (FDA).Multi\u2010disciplinary Review and Evaluation\u2014LUMAKRAS (Sotorasib); 2020.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/214665Orig1s000MultidisciplineR.pdf"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01192-5"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1489"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1392"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1501"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12327"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70326","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70326","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:07:17Z","timestamp":1787760437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1002\/ijc.70326"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70326","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"2025-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}